Contributo scientifico, sviluppato generalmente su uno specifico argomento, che illustra risultati originali di una ricerca o presenta caratteristiche di review, cioè di discussione dello stato dell’arte o della letteratura entro un ambito scientifico definito. La rivista di pubblicazione deve presentare caratteristiche di scientificità. La tipologia non comprende editoriali, commenti brevi, repliche, abstract, errata, recensioni e prodotti similari, per i quali sono previste specifiche tipologie.
Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia
2014 Finazzi, G; Carobbio, A; Guglielmelli, P; Cavalloni, C; Salmoiraghi, S; Vannucchi, Am; Cazzola, M; Passamonti, F; Rambaldi, A; Barbui, T
Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study
2014 Martinelli, I; De Stefano, V; Carobbio, A; Randi, Ml; Santarossa, C; Rambaldi, A; Finazzi, Mc; Cervantes, F; Arellano-Rodrigo, E; Rupoli, S; Canafoglia, L; Tieghi, A; Facchini, L; Betti, S; Vannucchi, Am; Pieri, L; Cacciola, R; Cacciola, E; Cortelezzi, A; Iurlo, A; Pogliani, Em; Elli, Em; Spadea, A; Barbui, T
PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics
2014 Massi, D; Brusa, D; Merelli, B; Ciano, M; Audrito, V; Serra, S; Buonincontri, R; Baroni, G; Nassini, R; Minocci, D; Cattaneo, L; Tamborini, E; Carobbio, A; Rulli, E; Deaglio, S; Mandala, M
Masked polycythemia vera (mPV): results of an international study
2014 Barbui, T; Thiele, J; Gisslinger, H; Finazzi, G; Carobbio, A; Rumi, E; Randi, Ml; Bertozzi, I; Vannucchi, Am; Pieri, L; Carrai, V; Gisslinger, B; Mullauer, L; Ruggeri, M; Rambaldi, A; Tefferi, A
Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19
2022 Gori, Mauro; Ghirardi, Arianna; D'Elia, Emilia; Imeri, Gianluca; Di Marco, Fabiano; Gavazzi, Antonello; Carobbio, Alessandra; Balestrieri, Giulio; Giammarresi, Andrea; Trevisan, Roberto; Amoroso, Mariangela; Raimondi, Federico; Novelli, Luca; Magro, Bianca; Mangia, Gianpaolo; Lorini, Ferdinando L; Fagiuoli, Stefano; Barbui, Tiziano; Rizzi, Marco; Cosentini, Roberto; Sironi, Sandro; Senni, Michele
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia
2010 Antonioli, E; Carobbio, A; Pieri, L; Pancrazzi, A; Guglielmelli, P; Delaini, F; Ponziani, V; Bartalucci, N; Tozzi, L; Bosi, A; Rambaldi, A; Barbui, T; Vannucchi, Am
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera
2014 Lussana, F; Carobbio, A; Randi, Ml; Elena, C; Rumi, E; Finazzi, G; Bertozzi, I; Pieri, L; Ruggeri, M; Palandri, F; Polverelli, N; Elli, E; Tieghi, A; Iurlo, A; Ruella, M; Cazzola, M; Rambaldi, A; Vannucchi, Am; Barbui, T
Diagnostic impact of the 2016 revised who criteria for polycythemia vera
2017 Barbui, T; Thiele, J; Gisslinger, H; Carobbio, A; Vannucchi, Am; Tefferi, A
Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status
2007 Carobbio, A; Finazzi, G; Guerini, V; Spinelli, O; Delaini, F; Marchioli, R; Borrelli, G; Rambaldi, A; Barbui, T
Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients
2014 Barbui, T; Thiele, J; Carobbio, A; Guglielmelli, P; Rambaldi, A; Vannucchi, Am; Tefferi, A
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia
2012 Carobbio, A; Finazzi, G; Thiele, J; Kvasnicka, Hm; Passamonti, F; Rumi, E; Ruggeri, M; Rodeghiero, F; Randi, Ml; Bertozzi, I; Vannucchi, Am; Antonioli, E; Gisslinger, H; Buxhofer-Ausch, V; Gangat, N; Rambaldi, A; Tefferi, A; Barbui, T
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients
2012 Buxhofer-Ausch, V; Gisslinger, H; Thiele, J; Gisslinger, B; Kvasnicka, Hm; Mullauer, L; Frantal, S; Carobbio, A; Passamonti, F; Rumi, E; Ruggeri, M; Rodeghiero, F; Randi, Ml; Bertozzi, I; Vannucchi, Am; Antonioli, E; Finazzi, G; Gangat, N; Tefferi, A; Barbui, T
One-year mortality in COVID-19 is associated with patients’ comorbidities rather than pneumonia severity
2023 Novelli, L.; Raimondi, F.; Carioli, G.; Carobbio, A.; Pappacena, S.; Biza, R.; Trapasso, R.; Anelli, M.; Amoroso, M.; Allegri, C.; Malandrino, L.; Imeri, G.; Conti, C.; Beretta, M.; Gori, M.; D'Elia, E.; Senni, M.; Lorini, F. L.; Rizzi, M.; Cosentini, R.; Rambaldi, A.; Masciulli, A.; Gavazzi, A.; Solidoro, P.; Sironi, S.; Fagiuoli, S.; Barbui, T.; Marco, F. D.
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology
2014 Barbui, T; Carobbio, A; Rumi, E; Finazzi, G; Gisslinger, H; Rodeghiero, F; Randi, Ml; Rambaldi, A; Gisslinger, B; Pieri, L; Bertozzi, I; Casetti, I; Pardanani, A; Passamonti, F; Vannucchi, Am; Tefferi, A
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study
2019 Barbui, T; Ghirardi, A; Masciulli, A; Carobbio, A; Palandri, F; Vianelli, N; De Stefano, V; Betti, S; Di Veroli, A; Iurlo, A; Cattaneo, D; Delaini, F; Bonifacio, M; Scaffidi, L; Patriarca, A; Rumi, E; Casetti, Ic; Stephenson, C; Guglielmelli, P; Elli, Em; Palova, M; Bertolotti, L; Erez, D; Gomez, M; Wille, K; Perez-Encinas, M; Lunghi, F; Angona, A; Fox, Ml; Beggiato, E; Benevolo, G; Carli, G; Cacciola, R; Mcmullin, Mf; Tieghi, A; Recasens, V; Marchetti, M; Griesshammer, M; Alvarez-Larran, A; Vannucchi, Am; Finazzi, G
Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review
2018 Marchetti, M; Carobbio, A; Capitoni, E; Barbui, T
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F)
2008 Guerini, V; Barbui, V; Spinelli, O; Salvi, A; Dellacasa, C; Carobbio, A; Introna, M; Barbui, T; Golay, J; Rambaldi, A
CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis
2015 Finazzi, Mc; Carobbio, A; Cervantes, F; Isola, Im; Vannucchi, Am; Guglielmelli, P; Rambaldi, A; Finazzi, G; Barosi, G; Barbui, T
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer. A case-control study
2020 De Stefano, V; Ghirardi, A; Masciulli, A; Carobbio, A; Palandri, F; Vianelli, N; Rossi, E; Betti, S; Di Veroli, A; Iurlo, A; Cattaneo, D; Finazzi, G; Bonifacio, M; Scaffidi, L; Patriarca, A; Rumi, E; Casetti, Ic; Stephenson, C; Guglielmelli, P; Elli, Em; Palova, M; Rapezzi, D; Erez, D; Gomez, M; Wille, K; Perez-Encinas, M; Lunghi, F; Angona, A; Fox, Ml; Beggiato, E; Benevolo, G; Carli, G; Cacciola, R; Mcmullin, Mf; Tieghi, A; Recasens, V; Isfort, S; Marchetti, M; Griesshammer, M; Alvarez-Larran, A; Vannucchi, Am; Rambaldi, A; Barbui, T
Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status
2007 Finazzi, G; Rambaldi, A; Guerini, V; Carobbio, A; Barbui, T
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia | 1-gen-2014 | Finazzi, G; Carobbio, A; Guglielmelli, P; Cavalloni, C; Salmoiraghi, S; Vannucchi, Am; Cazzola, M; Passamonti, F; Rambaldi, A; Barbui, T | |
| Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study | 1-gen-2014 | Martinelli, I; De Stefano, V; Carobbio, A; Randi, Ml; Santarossa, C; Rambaldi, A; Finazzi, Mc; Cervantes, F; Arellano-Rodrigo, E; Rupoli, S; Canafoglia, L; Tieghi, A; Facchini, L; Betti, S; Vannucchi, Am; Pieri, L; Cacciola, R; Cacciola, E; Cortelezzi, A; Iurlo, A; Pogliani, Em; Elli, Em; Spadea, A; Barbui, T | |
| PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics | 1-gen-2014 | Massi, D; Brusa, D; Merelli, B; Ciano, M; Audrito, V; Serra, S; Buonincontri, R; Baroni, G; Nassini, R; Minocci, D; Cattaneo, L; Tamborini, E; Carobbio, A; Rulli, E; Deaglio, S; Mandala, M | |
| Masked polycythemia vera (mPV): results of an international study | 1-gen-2014 | Barbui, T; Thiele, J; Gisslinger, H; Finazzi, G; Carobbio, A; Rumi, E; Randi, Ml; Bertozzi, I; Vannucchi, Am; Pieri, L; Carrai, V; Gisslinger, B; Mullauer, L; Ruggeri, M; Rambaldi, A; Tefferi, A | |
| Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19 | 1-gen-2022 | Gori, Mauro; Ghirardi, Arianna; D'Elia, Emilia; Imeri, Gianluca; Di Marco, Fabiano; Gavazzi, Antonello; Carobbio, Alessandra; Balestrieri, Giulio; Giammarresi, Andrea; Trevisan, Roberto; Amoroso, Mariangela; Raimondi, Federico; Novelli, Luca; Magro, Bianca; Mangia, Gianpaolo; Lorini, Ferdinando L; Fagiuoli, Stefano; Barbui, Tiziano; Rizzi, Marco; Cosentini, Roberto; Sironi, Sandro; Senni, Michele | |
| Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia | 1-gen-2010 | Antonioli, E; Carobbio, A; Pieri, L; Pancrazzi, A; Guglielmelli, P; Delaini, F; Ponziani, V; Bartalucci, N; Tozzi, L; Bosi, A; Rambaldi, A; Barbui, T; Vannucchi, Am | |
| A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera | 1-gen-2014 | Lussana, F; Carobbio, A; Randi, Ml; Elena, C; Rumi, E; Finazzi, G; Bertozzi, I; Pieri, L; Ruggeri, M; Palandri, F; Polverelli, N; Elli, E; Tieghi, A; Iurlo, A; Ruella, M; Cazzola, M; Rambaldi, A; Vannucchi, Am; Barbui, T | |
| Diagnostic impact of the 2016 revised who criteria for polycythemia vera | 1-gen-2017 | Barbui, T; Thiele, J; Gisslinger, H; Carobbio, A; Vannucchi, Am; Tefferi, A | |
| Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status | 1-gen-2007 | Carobbio, A; Finazzi, G; Guerini, V; Spinelli, O; Delaini, F; Marchioli, R; Borrelli, G; Rambaldi, A; Barbui, T | |
| Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients | 1-gen-2014 | Barbui, T; Thiele, J; Carobbio, A; Guglielmelli, P; Rambaldi, A; Vannucchi, Am; Tefferi, A | |
| Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia | 1-gen-2012 | Carobbio, A; Finazzi, G; Thiele, J; Kvasnicka, Hm; Passamonti, F; Rumi, E; Ruggeri, M; Rodeghiero, F; Randi, Ml; Bertozzi, I; Vannucchi, Am; Antonioli, E; Gisslinger, H; Buxhofer-Ausch, V; Gangat, N; Rambaldi, A; Tefferi, A; Barbui, T | |
| Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients | 1-gen-2012 | Buxhofer-Ausch, V; Gisslinger, H; Thiele, J; Gisslinger, B; Kvasnicka, Hm; Mullauer, L; Frantal, S; Carobbio, A; Passamonti, F; Rumi, E; Ruggeri, M; Rodeghiero, F; Randi, Ml; Bertozzi, I; Vannucchi, Am; Antonioli, E; Finazzi, G; Gangat, N; Tefferi, A; Barbui, T | |
| One-year mortality in COVID-19 is associated with patients’ comorbidities rather than pneumonia severity | 1-gen-2023 | Novelli, L.; Raimondi, F.; Carioli, G.; Carobbio, A.; Pappacena, S.; Biza, R.; Trapasso, R.; Anelli, M.; Amoroso, M.; Allegri, C.; Malandrino, L.; Imeri, G.; Conti, C.; Beretta, M.; Gori, M.; D'Elia, E.; Senni, M.; Lorini, F. L.; Rizzi, M.; Cosentini, R.; Rambaldi, A.; Masciulli, A.; Gavazzi, A.; Solidoro, P.; Sironi, S.; Fagiuoli, S.; Barbui, T.; Marco, F. D. | |
| In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology | 1-gen-2014 | Barbui, T; Carobbio, A; Rumi, E; Finazzi, G; Gisslinger, H; Rodeghiero, F; Randi, Ml; Rambaldi, A; Gisslinger, B; Pieri, L; Bertozzi, I; Casetti, I; Pardanani, A; Passamonti, F; Vannucchi, Am; Tefferi, A | |
| Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study | 1-gen-2019 | Barbui, T; Ghirardi, A; Masciulli, A; Carobbio, A; Palandri, F; Vianelli, N; De Stefano, V; Betti, S; Di Veroli, A; Iurlo, A; Cattaneo, D; Delaini, F; Bonifacio, M; Scaffidi, L; Patriarca, A; Rumi, E; Casetti, Ic; Stephenson, C; Guglielmelli, P; Elli, Em; Palova, M; Bertolotti, L; Erez, D; Gomez, M; Wille, K; Perez-Encinas, M; Lunghi, F; Angona, A; Fox, Ml; Beggiato, E; Benevolo, G; Carli, G; Cacciola, R; Mcmullin, Mf; Tieghi, A; Recasens, V; Marchetti, M; Griesshammer, M; Alvarez-Larran, A; Vannucchi, Am; Finazzi, G | |
| Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review | 1-gen-2018 | Marchetti, M; Carobbio, A; Capitoni, E; Barbui, T | |
| The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F) | 1-gen-2008 | Guerini, V; Barbui, V; Spinelli, O; Salvi, A; Dellacasa, C; Carobbio, A; Introna, M; Barbui, T; Golay, J; Rambaldi, A | |
| CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis | 1-gen-2015 | Finazzi, Mc; Carobbio, A; Cervantes, F; Isola, Im; Vannucchi, Am; Guglielmelli, P; Rambaldi, A; Finazzi, G; Barosi, G; Barbui, T | |
| Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer. A case-control study | 1-gen-2020 | De Stefano, V; Ghirardi, A; Masciulli, A; Carobbio, A; Palandri, F; Vianelli, N; Rossi, E; Betti, S; Di Veroli, A; Iurlo, A; Cattaneo, D; Finazzi, G; Bonifacio, M; Scaffidi, L; Patriarca, A; Rumi, E; Casetti, Ic; Stephenson, C; Guglielmelli, P; Elli, Em; Palova, M; Rapezzi, D; Erez, D; Gomez, M; Wille, K; Perez-Encinas, M; Lunghi, F; Angona, A; Fox, Ml; Beggiato, E; Benevolo, G; Carli, G; Cacciola, R; Mcmullin, Mf; Tieghi, A; Recasens, V; Isfort, S; Marchetti, M; Griesshammer, M; Alvarez-Larran, A; Vannucchi, Am; Rambaldi, A; Barbui, T | |
| Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status | 1-gen-2007 | Finazzi, G; Rambaldi, A; Guerini, V; Carobbio, A; Barbui, T |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- Contributo su RIVISTA69851
- Atti di CONVEGNO1
- Contributo su VOLUME1
Data di pubblicazione
- 2020 - 202720192
- 2010 - 201923511
- 2000 - 200914315
- 1990 - 19998032
- 1980 - 19893149
- 1970 - 1979640
- 1966 - 196911
Editore
- Elsevier BV:PO Box 211, 1000 AE A...334
- American Institute of Physics:2 H...226
- Elsevier Science Limited:Oxford F...189
- Giuffre Editore Spa:via Busto Ars...101
- Societa Editrice il Mulino Spa:St...73
- Springer Verlag Germany:Tiergarte...71
- IEEE / Institute of Electrical an...70
- Academic Press Incorporated:6277 ...67
- American Chemical Society:1155 Si...63
- Edizioni Minerva Medica:Corso Bra...59
Rivista
- JOURNAL OF HIGH ENERGY PHYSICS404
- EFSA JOURNAL380
- PLOS ONE315
- PHYSICAL REVIEW LETTERS309
- PHYSICAL REVIEW. B, CONDENSED MAT...294
- SCIENTIFIC REPORTS290
Serie
- EUROPEAN DISTANCE AND E-LEARNING ...1
Keyword
- Humans4564
- Female2681
- Male2251
- Middle Aged1673
- Adult1526
- Aged1328
- Italy767
- Treatment Outcome649
- COVID-19587
- 80 and over506
Lingua
- eng58327
- ita10772
- fre334
- spa299
- ger189
- por61
- rus24
- und23
- chi15
- pol6
Accesso al fulltext
- no fulltext29929
- open19773
- reserved18695
- partially open1440
- embargoed15
- mixed1
